Medical - Care Facilities
Compare Stocks
5 / 10Stock Comparison
USPH vs ACHC vs SEM vs SGRY vs ENSG
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
Medical - Care Facilities
USPH vs ACHC vs SEM vs SGRY vs ENSG — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities | Medical - Care Facilities |
| Market Cap | $897M | $2.25B | $2.04B | $1.87B | $10.18B |
| Revenue (TTM) | $695M | $3.37B | $5.52B | $3.34B | $5.27B |
| Net Income (TTM) | $11M | $-1.11B | $134M | $-76M | $363M |
| Gross Margin | 22.0% | 56.2% | 10.6% | 22.8% | 15.2% |
| Operating Margin | 12.2% | 11.7% | 5.8% | 11.8% | 8.5% |
| Forward P/E | 20.6x | 16.4x | 13.1x | 38.0x | 23.2x |
| Total Debt | $426M | $2.65B | $3.70B | $4.02B | $4.15B |
| Cash & Equiv. | $36M | $133M | $27M | $240M | $504M |
USPH vs ACHC vs SEM vs SGRY vs ENSG — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| U.S. Physical Thera… (USPH) | 100 | 79.6 | -20.4% |
| Acadia Healthcare C… (ACHC) | 100 | 85.5 | -14.5% |
| Select Medical Hold… (SEM) | 100 | 189.2 | +89.2% |
| Surgery Partners, I… (SGRY) | 100 | 106.8 | +6.8% |
| The Ensign Group, I… (ENSG) | 100 | 398.7 | +298.7% |
Price return only. Dividends and distributions are not included.
Quick Verdict: USPH vs ACHC vs SEM vs SGRY vs ENSG
Each card shows where this stock fits in a portfolio — not just who wins on paper.
USPH is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 5 yrs, beta 0.93, yield 3.1%
- 3.1% yield, 5-year raise streak, vs ENSG's 0.1%, (2 stocks pay no dividend)
ACHC lags the leaders in this set but could rank higher in a more targeted comparison.
SEM ranks third and is worth considering specifically for value.
- Lower P/E (13.1x vs 23.2x)
Among these 5 stocks, SGRY doesn't own a clear edge in any measured category.
ENSG carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 18.7%, EPS growth 14.1%, 3Y rev CAGR 18.7%
- 7.5% 10Y total return vs SEM's 158.5%
- Lower volatility, beta 0.42, current ratio 1.42x
- Beta 0.42, yield 0.1%, current ratio 1.42x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 18.7% revenue growth vs ACHC's 5.0% | |
| Value | Lower P/E (13.1x vs 23.2x) | |
| Quality / Margins | 6.9% margin vs ACHC's -32.8% | |
| Stability / Safety | Beta 0.42 vs SGRY's 1.04 | |
| Dividends | 3.1% yield, 5-year raise streak, vs ENSG's 0.1%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +27.5% vs SGRY's -38.2% | |
| Efficiency (ROA) | 6.8% ROA vs ACHC's -18.6%, ROIC 7.0% vs 5.9% |
USPH vs ACHC vs SEM vs SGRY vs ENSG — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
USPH vs ACHC vs SEM vs SGRY vs ENSG — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
ENSG leads in 3 of 6 categories
SEM leads 1 • USPH leads 0 • ACHC leads 0 • SGRY leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
ENSG leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
SEM is the larger business by revenue, generating $5.5B annually — 7.9x USPH's $695M. ENSG is the more profitable business, keeping 6.9% of every revenue dollar as net income compared to ACHC's -32.8%. On growth, ENSG holds the edge at +18.4% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $695M | $3.4B | $5.5B | $3.3B | $5.3B |
| EBITDAEarnings before interest/tax | $107M | $588M | $465M | $572M | $558M |
| Net IncomeAfter-tax profit | $11M | -$1.1B | $134M | -$76M | $363M |
| Free Cash FlowCash after capex | $67M | -$215M | $117M | $208M | $406M |
| Gross MarginGross profit ÷ Revenue | +22.0% | +56.2% | +10.6% | +22.8% | +15.2% |
| Operating MarginEBIT ÷ Revenue | +12.2% | +11.7% | +5.8% | +11.8% | +8.5% |
| Net MarginNet income ÷ Revenue | +1.5% | -32.8% | +2.4% | -2.3% | +6.9% |
| FCF MarginFCF ÷ Revenue | +9.6% | -6.4% | +2.1% | +6.2% | +7.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +7.7% | +7.6% | +5.0% | +4.5% | +18.4% |
| EPS Growth (YoY)Latest quarter vs prior year | -115.0% | -49.8% | -18.2% | +6.7% | +21.9% |
Valuation Metrics
SEM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
At 13.9x trailing earnings, SEM trades at a 66% valuation discount to USPH's 41.5x P/E. On an enterprise value basis, ACHC's 8.3x EV/EBITDA is more attractive than ENSG's 25.7x.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $897M | $2.3B | $2.0B | $1.9B | $10.2B |
| Enterprise ValueMkt cap + debt − cash | $1.3B | $4.8B | $5.7B | $5.7B | $13.8B |
| Trailing P/EPrice ÷ TTM EPS | 41.55x | -2.01x | 13.93x | -23.46x | 29.85x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.63x | 16.42x | 13.06x | 37.99x | 23.19x |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | 2.16x |
| EV / EBITDAEnterprise value multiple | 12.52x | 8.27x | 12.04x | 10.00x | 25.71x |
| Price / SalesMarket cap ÷ Revenue | 1.15x | 0.68x | 0.37x | 0.57x | 2.01x |
| Price / BookPrice ÷ Book value/share | 1.16x | 1.04x | 1.00x | 0.52x | 4.59x |
| Price / FCFMarket cap ÷ FCF | 14.71x | — | 5.33x | 9.57x | 27.46x |
Profitability & Efficiency
ENSG leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
ENSG delivers a 16.6% return on equity — every $100 of shareholder capital generates $17 in annual profit, vs $-41 for ACHC. USPH carries lower financial leverage with a 0.55x debt-to-equity ratio, signaling a more conservative balance sheet compared to ENSG's 1.86x.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +1.4% | -40.9% | +6.6% | -2.2% | +16.6% |
| ROA (TTM)Return on assets | +0.9% | -18.6% | +2.3% | -0.9% | +6.8% |
| ROICReturn on invested capital | +5.6% | +5.9% | +4.8% | +4.1% | +7.0% |
| ROCEReturn on capital employed | +7.6% | +7.5% | +7.0% | +5.2% | +10.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 | 5 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.55x | 1.24x | 1.82x | 1.14x | 1.86x |
| Net DebtTotal debt minus cash | $390M | $2.5B | $3.7B | $3.8B | $3.7B |
| Cash & Equiv.Liquid assets | $36M | $133M | $27M | $240M | $504M |
| Total DebtShort + long-term debt | $426M | $2.7B | $3.7B | $4.0B | $4.2B |
| Interest CoverageEBIT ÷ Interest expense | 15.42x | -5.99x | 4.41x | 1.35x | 88.33x |
Total Returns (Dividends Reinvested)
ENSG leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ENSG five years ago would be worth $20,324 today (with dividends reinvested), compared to $2,773 for SGRY. Over the past 12 months, ENSG leads with a +27.5% total return vs SGRY's -38.2%. The 3-year compound annual growth rate (CAGR) favors ENSG at 23.6% vs ACHC's -29.2% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -24.6% | +71.2% | +11.4% | -6.2% | +0.3% |
| 1-Year ReturnPast 12 months | -14.3% | +1.2% | +11.1% | -38.2% | +27.5% |
| 3-Year ReturnCumulative with dividends | -43.7% | -64.5% | +7.4% | -59.2% | +88.9% |
| 5-Year ReturnCumulative with dividends | -43.4% | -61.8% | -11.1% | -72.3% | +103.2% |
| 10-Year ReturnCumulative with dividends | +22.6% | -58.5% | +158.5% | -0.6% | +752.0% |
| CAGR (3Y)Annualised 3-year return | -17.4% | -29.2% | +2.4% | -25.8% | +23.6% |
Risk & Volatility
Evenly matched — SEM and ENSG each lead in 1 of 2 comparable metrics.
Risk & Volatility
ENSG is the less volatile stock with a 0.42 beta — it tends to amplify market swings less than SGRY's 1.04 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. SEM currently trades 96.8% from its 52-week high vs SGRY's 59.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.93x | 0.84x | 0.46x | 1.04x | 0.42x |
| 52-Week HighHighest price in past year | $93.50 | $30.20 | $16.99 | $24.18 | $218.00 |
| 52-Week LowLowest price in past year | $58.55 | $11.43 | $11.65 | $11.41 | $133.81 |
| % of 52W HighCurrent price vs 52-week peak | +63.1% | +81.0% | +96.8% | +59.2% | +80.0% |
| RSI (14)Momentum oscillator 0–100 | 46.1 | 46.2 | 60.9 | 63.3 | 23.3 |
| Avg Volume (50D)Average daily shares traded | 171K | 3.1M | 2.1M | 1.5M | 358K |
Analyst Outlook
Evenly matched — USPH and ENSG each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: USPH as "Buy", ACHC as "Buy", SEM as "Hold", SGRY as "Buy", ENSG as "Buy". Consensus price targets imply 72.9% upside for USPH (target: $102) vs -3.9% for ACHC (target: $24). For income investors, USPH offers the higher dividend yield at 3.06% vs ENSG's 0.14%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Hold | Buy | Buy |
| Price TargetConsensus 12-month target | $102.00 | $23.50 | $18.00 | $18.60 | $222.33 |
| # AnalystsCovering analysts | 12 | 25 | 13 | 22 | 13 |
| Dividend YieldAnnual dividend ÷ price | +3.1% | — | +1.5% | — | +0.1% |
| Dividend StreakConsecutive years of raises | 5 | 1 | 0 | 0 | 12 |
| Dividend / ShareAnnual DPS | $1.80 | — | $0.25 | — | $0.24 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.6% | +2.2% | +4.9% | 0.0% | +0.2% |
ENSG leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). SEM leads in 1 (Valuation Metrics). 2 tied.
USPH vs ACHC vs SEM vs SGRY vs ENSG: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is USPH or ACHC or SEM or SGRY or ENSG a better buy right now?
For growth investors, The Ensign Group, Inc.
(ENSG) is the stronger pick with 18. 7% revenue growth year-over-year, versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). Select Medical Holdings Corporation (SEM) offers the better valuation at 13. 9x trailing P/E (13. 1x forward), making it the more compelling value choice. Analysts rate U. S. Physical Therapy, Inc. (USPH) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — USPH or ACHC or SEM or SGRY or ENSG?
On trailing P/E, Select Medical Holdings Corporation (SEM) is the cheapest at 13.
9x versus U. S. Physical Therapy, Inc. at 41. 5x. On forward P/E, Select Medical Holdings Corporation is actually cheaper at 13. 1x.
03Which is the better long-term investment — USPH or ACHC or SEM or SGRY or ENSG?
Over the past 5 years, The Ensign Group, Inc.
(ENSG) delivered a total return of +103. 2%, compared to -72. 3% for Surgery Partners, Inc. (SGRY). Over 10 years, the gap is even starker: ENSG returned +752. 0% versus ACHC's -58. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — USPH or ACHC or SEM or SGRY or ENSG?
By beta (market sensitivity over 5 years), The Ensign Group, Inc.
(ENSG) is the lower-risk stock at 0. 42β versus Surgery Partners, Inc. 's 1. 04β — meaning SGRY is approximately 147% more volatile than ENSG relative to the S&P 500. On balance sheet safety, U. S. Physical Therapy, Inc. (USPH) carries a lower debt/equity ratio of 55% versus 186% for The Ensign Group, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — USPH or ACHC or SEM or SGRY or ENSG?
By revenue growth (latest reported year), The Ensign Group, Inc.
(ENSG) is pulling ahead at 18. 7% versus 5. 0% for Acadia Healthcare Company, Inc. (ACHC). On earnings-per-share growth, the picture is similar: Surgery Partners, Inc. grew EPS 54. 1% year-over-year, compared to -537. 4% for Acadia Healthcare Company, Inc.. Over a 3-year CAGR, ENSG leads at 18. 7% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — USPH or ACHC or SEM or SGRY or ENSG?
The Ensign Group, Inc.
(ENSG) is the more profitable company, earning 6. 8% net margin versus -33. 3% for Acadia Healthcare Company, Inc. — meaning it keeps 6. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SGRY leads at 11. 8% versus 6. 1% for SEM. At the gross margin level — before operating expenses — SGRY leads at 23. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is USPH or ACHC or SEM or SGRY or ENSG more undervalued right now?
On forward earnings alone, Select Medical Holdings Corporation (SEM) trades at 13.
1x forward P/E versus 38. 0x for Surgery Partners, Inc. — 24. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for USPH: 72. 9% to $102. 00.
08Which pays a better dividend — USPH or ACHC or SEM or SGRY or ENSG?
In this comparison, USPH (3.
1% yield), SEM (1. 5% yield), ENSG (0. 1% yield) pay a dividend. ACHC, SGRY do not pay a meaningful dividend and should not be held primarily for income.
09Is USPH or ACHC or SEM or SGRY or ENSG better for a retirement portfolio?
For long-horizon retirement investors, Select Medical Holdings Corporation (SEM) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
46), 1. 5% yield, +158. 5% 10Y return). Both have compounded well over 10 years (SEM: +158. 5%, SGRY: -0. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between USPH and ACHC and SEM and SGRY and ENSG?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: USPH is a small-cap high-growth stock; ACHC is a small-cap quality compounder stock; SEM is a small-cap deep-value stock; SGRY is a small-cap quality compounder stock; ENSG is a mid-cap high-growth stock. USPH, SEM pay a dividend while ACHC, SGRY, ENSG do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.